Announcement on behalf of AP Biosciences that preemptive rights forfeited by all directors are over 50% and made available to specific persons

1.Date of occurrence of the event:2022/08/31
2.Reason for the forfeiture of subscription rights by the directors nd supervisors:
In accordance with related laws and regulations, to coordinate with AP Bioscineces’ future plan of shareholding dispersal after IPO, directors of AP Biosciences decide to forfeit all the preemptive rights of its 2022 cash capital increase and make it available to specific persons.
3.Name of director/supervisor, number of shares forfeited, and the percentage out of total subscription:
Director: OBI Pharma Inc.
7,864,657 shares forfeited, percentage out of total subscription: 100%
Director: AbProtix Inc.
1,949,622 shares forfeited, percentage out of total subscription: 100%
4.Name(s) of the specific person(s) and no.of shares subscribed:
(1)OBI Pharma Inc. forfeited 7,864,657 shares available, which were designated to the OBI’s shareholders. Based on the shareholding ratio stated on the register of shareholders on the book closure date of OBI, each thousand shares of OBI bears the subscription rights for 34.3016 shares of AP Biosciences.
(2)AbProtix Inc. forfeited 1,949,622 shares. The Chairman of AP Biosciences was authorized to contact specific persons for purchase at issue price for shares forfeited.
5.Any other matters that need to be specified:None